Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Decreases By 14.9%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a drop of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily volume of 895,400 shares, the days-to-cover ratio is currently 4.4 days. Approximately 7.1% of the company’s shares are short sold.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $33,000. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $39,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at $53,000. Sterling Capital Management LLC raised its holdings in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the period.

Agios Pharmaceuticals Stock Up 3.3 %

NASDAQ AGIO opened at $32.71 on Friday. The firm has a 50-day moving average price of $33.44 and a two-hundred day moving average price of $41.43. The company has a market capitalization of $1.87 billion, a P/E ratio of 2.88 and a beta of 0.90. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.